Welcome to StromaBio AB, where we are focused on advancing Mesenchymal Stromal Cell (MSC)-based therapies. Our work targets acute and chronic conditions, with a current focus on Acute Respiratory Distress Syndrome (ARDS) and Alzheimer’s Disease (AD).
With over two decades of research as our foundation, we are dedicated to unlocking the potential of MSCs, which offer anti-inflammatory, immune-modulatory, and regenerative benefits. Our aim is to develop treatments that address critical medical needs and improve patient outcomes.
At StromaBio, we are committed to innovation and making a difference. By promoting regeneration and reducing inflammation, our therapies have the potential to enhance lives and support global healthcare.
We are building a team passionate about shaping the future of cell-based treatments. Whether you are a partner, investor, or job seeker, we welcome you to connect with us and be part of this journey.
Company Details
- Employees
- 5
- Founded
- -
- Address
- Critical Medical Needs And Improve Patient Outcomes.
- Industry
- Biotechnology
- Website
- https://stromabio.se/
Stromabio Questions
Stromabio's website is https://stromabio.se/
Stromabio's LinkedIn profile is https://www.linkedin.com/company/stromabio-ab
Stromabio has
5 employees.
View email and phone details for 5
employees at Stromabio.
Stromabio's industry is
Biotechnology
Stromabio's top competitors are
Navinci,
Asthmatuner By Medituner Ab,
Cellcolabs,
Curacell,
Atmp Sweden,
Anteris,
Aplex Bio,
Takura Ab,
Basic Genomics Ab,
Salipro Biotech Ab.
Stromabio's categories are Biotechnology
Stromabio's founding year is 2018
